Peripheral arterial disease (PAD) nursing: assessment, management, and NCLEX review

Peripheral arterial disease (PAD) is a chronic, progressive condition in which atherosclerotic narrowing of the peripheral arteries — most often the lower extremities — reduces blood flow to the limbs. Approximately 12% of adults in the United States have PAD, with prevalence rising sharply in people over 50 and in those with diabetes or a history of smoking. PAD is far more than a leg problem: it is a powerful marker of systemic atherosclerosis, and patients with PAD carry a two- to three-fold increased risk of myocardial infarction and stroke compared to those without it. Nursing students must understand PAD because they will encounter it across nearly every clinical setting — med-surg, vascular surgery, the ICU, wound care, and outpatient primary care — and because it generates some of the highest-yield NCLEX distinctions in cardiovascular nursing, particularly around wound assessment, positioning, and management differences between arterial and venous disease.

ABI quick reference

Pathophysiology and risk factors

How arterial occlusion develops

PAD begins with intimal injury — damage to the innermost layer of the arterial wall. The triggers are the same ones that drive coronary artery disease: shear stress from hypertension, oxidative damage from smoking, hyperglycemia, and dyslipidemia. Once the endothelium is disrupted, low-density lipoprotein (LDL) cholesterol infiltrates the subintimal space and undergoes oxidation. Oxidized LDL triggers an inflammatory response: monocytes migrate into the intimal layer, differentiate into macrophages, and engulf oxidized LDL to become lipid-laden foam cells. These foam cells accumulate to form the fatty streak — the earliest visible lesion of atherosclerosis.

Over years to decades, smooth muscle cells migrate from the tunica media into the intimal layer and proliferate around the lipid core. The lesion grows into a fibroatheromatous plaque, which progressively narrows the arterial lumen. A fibrous cap of collagen overlies the necrotic lipid core. When the cap erodes or ruptures, platelet aggregation and thrombus formation can cause acute on chronic occlusion — a sudden escalation in symptoms that may precipitate critical limb ischemia.

As the arterial lumen narrows, resting blood flow can be maintained until stenosis exceeds approximately 50–70% of the vessel diameter. At that threshold, a pressure gradient develops across the lesion, and blood flow during exercise — when the distal muscles demand a two- to five-fold increase in oxygen delivery — can no longer meet metabolic demand. The resulting anaerobic metabolism produces lactic acid and adenosine, triggering the aching, cramping pain of intermittent claudication. As stenosis worsens, ischemia occurs at rest; eventually, the tissue cannot sustain viability and ischemic ulceration or gangrene develops.

Risk factors

Smoking is the single most important modifiable risk factor for PAD. Smokers have a two- to four-fold higher risk of PAD compared to non-smokers, and smoking accelerates atherosclerotic progression in the lower extremities disproportionately compared to the coronary or carotid circulations. Smoking cessation is the most impactful intervention available.

Diabetes mellitus doubles the risk of PAD and shifts the pattern of disease toward the smaller infrapopliteal vessels (tibial and peroneal arteries), making revascularization technically more difficult. Peripheral neuropathy in diabetics compounds the danger: patients lose protective pain sensation, so critical ischemia may go unnoticed until tissue loss is advanced. See the diabetes mellitus nursing reference for related care principles.

Hypertension accelerates intimal injury via chronic mechanical shear stress. Even partially controlled blood pressure significantly increases PAD progression. The hypertension nursing reference covers BP management targets relevant to vascular disease.

Hyperlipidemia — specifically elevated LDL and low HDL — provides the substrate for atherosclerotic plaque formation. Statin therapy reduces both PAD progression and systemic cardiovascular events.

Age over 50 is a strong non-modifiable risk factor; the prevalence of PAD rises steeply after age 65. Additional risks include a family history of premature vascular disease, chronic kidney disease, and prior history of myocardial infarction or stroke (which indicates systemic atherosclerosis).

Clinical presentation: from claudication to critical limb ischemia

Intermittent claudication

The classic symptom of PAD is intermittent claudication — reproducible cramping pain, aching, or heaviness in the exercising muscle that appears after a predictable walking distance and resolves completely with rest (within 2–5 minutes). The location of claudication correlates with the level of arterial disease: calf claudication suggests femoral-popliteal disease (most common); thigh and buttock claudication suggests aortoiliac disease (Leriche syndrome — claudication plus erectile dysfunction in men). The defining feature is symptom relief with stopping — not elevation, not positional change, simply stopping the exercise and allowing perfusion to recover. This distinguishes claudication from neurogenic claudication of lumbar spinal stenosis, which requires sitting or forward flexion for relief.

Rest pain

Rest pain marks the transition from intermittent claudication to chronic limb-threatening ischemia (CLTI). It occurs because the resting blood flow is insufficient to meet the baseline metabolic needs of the foot. Rest pain is characteristically located in the forefoot — the most distal, most metabolically demanding tissue — and is typically described as burning or aching. It worsens at night and with leg elevation (gravity removes the modest assist of hydrostatic pressure), and it is partially relieved by dangling the foot off the side of the bed or standing. Patients often sleep with the affected leg hanging down, which over time leads to dependent edema that can obscure the atrophic skin changes.

Tissue loss: ulcers and gangrene

Critical limb ischemia progresses to tissue loss in the form of ischemic ulcers — characteristically located on the tips of the toes, between toes, on the heel, or over pressure points and bony prominences. They are punched-out in appearance, with pale or necrotic bases, minimal exudate, and surrounding pale or cyanotic skin. They are painful — in contrast to the painless ulcers of diabetic neuropathy. When ischemia is severe and uncorrected, wet or dry gangrene develops, beginning distally at the toes. Infected ulcers in critical limb ischemia can progress to sepsis rapidly; see the sepsis nursing reference for recognition of systemic infection in compromised patients.

The 6 Ps of acute arterial occlusion

The 6 Ps — Pallor, Pulselessness, Pain, Paresthesia, Paralysis, and Poikilothermia (coldness) — describe the acute presentation of sudden arterial occlusion from embolism or acute thrombosis overlying a chronic plaque. This is a limb-threatening emergency requiring immediate vascular surgery consultation. The onset is sudden and dramatic, unlike the gradual progression of chronic PAD. In chronic PAD, findings are subtler: pulses may be diminished rather than absent, and the skin shows chronic atrophic changes rather than the sudden mottling of acute ischemia.

Chronic physical signs

On examination, the chronically ischemic limb shows hair loss on the dorsum of the foot and lower leg (due to reduced perfusion of hair follicles), atrophic, shiny, tight skin, thickened toenails, and a limb that is cooler than the contralateral side. Capillary refill is prolonged (greater than 3 seconds). The foot may be pale on elevation and take on a dependent rubor (deep red-purple color) when the leg is lowered, as blood pools passively into the dilated but barely perfused capillaries — a finding called Buerger’s test. Peripheral pulses — dorsalis pedis and posterior tibial — are diminished or absent.

Diagnosis

Ankle-brachial index

The ankle-brachial index (ABI) is the cornerstone of PAD diagnosis and is the first-line non-invasive test. It is calculated by dividing the higher of the two ankle systolic pressures (dorsalis pedis or posterior tibial) by the higher of the two brachial systolic pressures:

ABI = Ankle systolic pressure ÷ Brachial systolic pressure

A Doppler probe is used (not a standard stethoscope) to detect systolic flow at each site. The test is performed with the patient supine after at least 5–10 minutes of rest. An ABI of 1.0–1.4 is normal. Values below 0.9 confirm PAD; values at or below 0.4 indicate critical limb ischemia. Values above 1.4 are noncompressible (see table above) and require alternative testing such as the toe-brachial index (TBI), which is normal at ≥0.7. In diabetics and dialysis patients, vessel wall calcification is common — an ABI above 1.4 in these populations should not be misinterpreted as normal perfusion.

Vascular imaging

Duplex ultrasound combines B-mode imaging with Doppler flow measurement and is the first-line imaging test. It identifies stenosis location and severity without radiation or contrast and is used to plan revascularization. Limitations include operator dependence and difficulty imaging calcified or heavily diseased vessels.

CT angiography (CTA) provides detailed anatomical mapping of the aorta, iliac, femoral, popliteal, and tibial vessels and is widely used for pre-operative planning. It requires iodinated contrast (nephrotoxic — assess renal function before ordering) and radiation exposure.

MR angiography (MRA) avoids radiation and iodinated contrast (gadolinium used instead — watch for nephrogenic systemic fibrosis in severe CKD). It is used when CT contrast is contraindicated.

Conventional angiography (catheter-based) remains the gold standard for arterial imaging, providing the highest resolution and the ability to proceed directly to endovascular intervention during the same procedure. It carries a small risk of contrast nephropathy, access site bleeding, and distal embolization.

Medical management

Antiplatelet therapy

Antiplatelet therapy reduces the risk of myocardial infarction, stroke, and vascular death — the systemic cardiovascular events that are the primary cause of mortality in PAD patients. Aspirin 75–100 mg daily is the standard first-line agent. Clopidogrel 75 mg daily is an alternative for patients intolerant of aspirin and is preferred by some guidelines for symptomatic PAD; see the cardiovascular medications nursing reference for antiplatelet mechanism and monitoring. Dual antiplatelet therapy (aspirin plus clopidogrel) is used after certain endovascular procedures and in high-risk patients but increases bleeding risk. Nursing considerations: Assess for signs of bleeding (stool color, bruising, epistaxis). Educate patients not to stop antiplatelet therapy without provider guidance, as abrupt discontinuation increases thrombotic risk.

Statin therapy

Statins — primarily atorvastatin — are prescribed for all PAD patients regardless of baseline LDL level. The benefit in PAD is dual: LDL reduction stabilizes plaque (reduces plaque vulnerability to rupture) and, separately, statins have direct anti-inflammatory and endothelial-protective effects that slow PAD progression and reduce major cardiovascular events. High-intensity statin therapy (atorvastatin 40–80 mg) is recommended by the 2024 ACC/AHA peripheral vascular guidelines. Nursing considerations: Monitor for myopathy (muscle pain or weakness) and transaminase elevation, especially at higher doses.

ACE inhibitors

ACE inhibitors — ramipril is the most studied — improve walking distance, reduce cardiovascular events, and may have direct vascular protective effects in PAD beyond blood pressure reduction. They are recommended for most PAD patients, particularly those with coexisting hypertension, diabetes, or reduced cardiac function.

Cilostazol

Cilostazol (Pletal) is a phosphodiesterase III inhibitor that improves claudication symptoms by inhibiting platelet aggregation and promoting arterial vasodilation. It is approved as first-line pharmacotherapy for intermittent claudication, increasing pain-free and maximum walking distance by approximately 40–60% in clinical trials. Critical contraindication: cilostazol is contraindicated in any degree of heart failure. Phosphodiesterase III inhibitors increase intracellular cAMP in cardiac myocytes, which increases inotropy and carries a mortality risk in patients with reduced cardiac function — the same mechanism that caused increased deaths with milrinone in heart failure trials. See the heart failure nursing reference for HF assessment relevant to this contraindication. Nursing considerations: Assess for HF before administration. Common side effects include headache and palpitations (vasodilatory). Take 30 minutes before or 2 hours after meals for optimal absorption.

Supervised exercise therapy

Supervised exercise therapy (SET) is the most evidence-based intervention for intermittent claudication and is recommended as first-line treatment before considering revascularization in patients with claudication. Programs typically run 3 sessions per week for 12 weeks, with each session consisting of 30–45 minutes of treadmill walking. The protocol is walking-to-pain: the patient walks until near-maximal claudication pain, rests briefly, then resumes. This controlled ischemic stimulus drives collateral vessel development, improves endothelial function, and increases skeletal muscle oxidative capacity. Studies show SET is as effective as angioplasty for claudication outcomes in many patients, with a more favorable safety profile. SET is significantly underutilized in clinical practice due to access and reimbursement barriers. Nursing role: Educate patients that pain during exercise is expected and safe within the supervised program; encourage adherence.

Revascularization and surgical management

Revascularization is indicated for critical limb ischemia (rest pain, tissue loss) and for claudication that significantly limits quality of life and has not improved with conservative management.

Endovascular revascularization

Percutaneous transluminal angioplasty (PTA) involves advancing a balloon catheter to the site of stenosis, inflating the balloon to dilate the artery, and often deploying a stent to maintain lumen patency. It is performed via the femoral or radial artery under fluoroscopic guidance. PTA ± stenting is preferred for shorter, focal stenoses (particularly iliac disease), where long-term patency rates are acceptable. Access site complications — hematoma, pseudoaneurysm, and retroperitoneal bleeding from femoral access — are the most common adverse events. Post-procedure nursing care: Neurovascular checks (pulse, sensation, motor function, capillary refill, temperature) at the distal extremity every 15 minutes for 1 hour, then every 30 minutes for 2 hours, then hourly per protocol. Monitor the access site continuously for bleeding. Maintain the access leg straight for the prescribed time. Monitor for signs of distal embolization (new pain, pallor, pulselessness in the toes or foot).

Surgical bypass grafting

Bypass grafting creates an anatomic detour around the obstructed segment using the patient’s own saphenous vein (preferred — lower infection risk, superior long-term patency) or a synthetic graft (polytetrafluoroethylene, PTFE). Common procedures include femoral-popliteal bypass (for femoropopliteal disease), femoral-tibial bypass (for infrapopliteal disease), and aortoiliac reconstruction (for inflow disease). Bypass grafting offers better long-term patency than endovascular intervention for long-segment occlusions and diffuse disease, at the cost of greater procedural risk — particularly for patients with significant comorbidities.

Post-bypass nursing care: Neuro-vascular checks identical to post-endovascular care. Monitor for graft occlusion signs (sudden loss of distal pulse, new pain, pallor, coolness distally — escalate immediately). Manage anticoagulation per protocol (heparin infusion or antiplatelet therapy). Monitor surgical wound for hematoma or bleeding. Wound healing may be impaired in critical limb ischemia — see the wound assessment reference for principles of ischemic wound management. Leg position is dependent — do not elevate above heart level in patients with critical limb ischemia, as gravity assists perfusion.

Critical limb ischemia: when revascularization is not possible

When revascularization is anatomically impossible or carries prohibitive risk, amputation may be the only option to control infection, remove gangrenous tissue, and relieve unmanageable pain. Decisions are multidisciplinary and consider patient goals of care. Amputation at the lowest viable level preserves maximum function. Primary amputation is not failure — in patients with unsalvageable critical limb ischemia, it is a definitive treatment that relieves suffering.

PAD vs venous insufficiency vs acute arterial occlusion

This comparison table is one of the highest-yield distinctions in NCLEX vascular nursing. Students frequently confuse arterial and venous pathology, leading to errors in positioning, wound management, and intervention selection.

Nursing assessment and care priorities

Peripheral vascular assessment

A focused PAD assessment begins with bilateral comparison of the lower extremities:

Pulse assessment: Palpate the posterior tibial (behind the medial malleolus) and dorsalis pedis (dorsum of the foot, lateral to the extensor hallucis longus tendon) pulses bilaterally and grade: 0 = absent, 1 = diminished, 2 = normal, 3 = bounding. Pulses should be assessed with a Doppler if not palpable. Always compare symmetry — asymmetric pulses are more diagnostically significant than absent bilateral pulses in a patient with known PAD.

Skin and tissue assessment: Color (pallor, cyanosis, dependent rubor), temperature (use the dorsum of the hand to compare bilaterally), texture (atrophic, shiny, tight), hair distribution, nail changes. Document the lowest level at which normal skin changes are found — this corresponds approximately to the level of perfusion compromise.

Capillary refill: Press the nail bed or toe pulp until blanching, then release. Refill in more than 3 seconds suggests reduced arterial perfusion.

Wound assessment: If ulceration is present, assess location, size, depth, wound base (pale, necrotic, granular), periwound skin, pain level, and signs of infection (erythema, warmth, purulence, malodor). Ischemic ulcers with infection are limb-threatening — escalate promptly. Apply wound care principles from the wound assessment reference; avoid occlusive dressings that trap moisture in an ischemic wound.

Pain assessment: Claudication distance (how far the patient can walk before pain), rest pain characteristics, and pain with positioning changes. Use a 0–10 numeric rating scale. Track changes over time — increasing rest pain or shorter claudication distance signals disease progression.

Tissue care in critical limb ischemia

• Protect the heels — use heel-lift foam boots or pillows placed under the calves (not heels) to float the heels off the bed. Heel pressure ulcers in an ischemic limb progress to full-thickness necrosis rapidly.
• Dependent positioning — keep the affected leg level or slightly below the level of the heart. Do not elevate above heart level — this reduces the small perfusion pressure gradient that gravity provides.
• Do not apply compression — never use compression stockings, ACE wraps, or sequential compression devices on an ischemic limb. Compression further reduces arterial inflow. This is the single most important NCLEX distinction between PAD and venous insufficiency management.
• Avoid heating pads and hot soaks — peripheral neuropathy (especially in diabetics) makes patients unable to perceive burn injury. Increased metabolic demand from heat exceeds the ischemic limb’s limited supply.
• Meticulous wound care — keep wounds clean and covered; consult wound care specialty; avoid tight bandaging.

Post-procedure monitoring

After endovascular or surgical revascularization, neurovascular checks must be performed systematically:

1. Pulses (dorsalis pedis and posterior tibial distal to the procedure or graft)
2. Capillary refill (should be less than 3 seconds)
3. Skin color and temperature
4. Sensation (paresthesia or numbness may signal nerve ischemia)
5. Motor function (ask the patient to move toes and foot)

Document and compare to the baseline pre-procedure assessment. A sudden loss of previously palpable pulse, new pallor, or new neurological deficit requires immediate escalation and potential return to the operating room for graft occlusion or procedural complication.

Patient education

Effective patient education addresses the modifiable risk factors and the specific self-care priorities that prevent amputation.

Smoking cessation is the single most important teaching point. Continued smoking after PAD diagnosis doubles amputation risk and negates much of the benefit of revascularization. Refer to cessation programs, pharmacotherapy (nicotine replacement, varenicline, bupropion), and provide repeated, non-judgmental counseling. Most patients require multiple attempts before sustained cessation.

Foot inspection and care: Inspect feet daily using a mirror if necessary — sensory loss in diabetic neuropathy prevents pain-based detection of injury. Look for blisters, cuts, cracks between toes, and color changes. Never walk barefoot. Wear properly fitting shoes and check inside the shoe for foreign objects before putting them on. Trim nails straight across; seek podiatry care for thickened nails and calluses. Do not use heating pads, hot water bottles, or soak feet in hot water. Keep feet clean and moisturized (avoid between toes — fungal growth risk). Report any new ulcer, color change, or swelling to the provider immediately — early intervention prevents critical limb ischemia. See the diabetes mellitus nursing reference for diabetic foot care principles.

Exercise adherence: Supervised walking programs are among the most effective PAD treatments available. Reassure patients that walking through claudication pain is safe within the supervised program and that the discomfort diminishes over weeks as collateral circulation improves.

Medication compliance: Emphasize that antiplatelet and statin therapy reduce heart attack and stroke risk — the main causes of death in PAD — as well as protecting the limbs. Patients often feel asymptomatic between claudication episodes and may deprioritize medications; reinforce the systemic benefit.

Risk factor control: Blood pressure targets (less than 130/80 mmHg for most patients), blood glucose management (HbA1c less than 7% for most diabetics), and LDL reduction (less than 70 mg/dL for high-risk PAD) all slow disease progression.

Medical management summary

Fontaine stages

NCLEX tips

1. ABI ≤0.40 = critical limb ischemia. This is the threshold for urgent revascularization evaluation. Below 0.40, the limb is at immediate risk of tissue loss.

2. ABI >1.4 is NOT normal. In diabetics and patients with CKD, calcified vessels cannot be compressed — the ABI is falsely elevated. Order a toe-brachial index (TBI) instead. Never assume an ABI above 1.4 means good perfusion.

3. Cilostazol is contraindicated in heart failure — all classes, all ejection fractions. This is one of the most commonly tested PAD drug contraindications. Before administering, confirm the patient has no current or prior HF diagnosis.

4. Positioning: PAD = dependent; venous insufficiency = elevated. In PAD and critical limb ischemia, legs should be level or slightly dependent — gravity assists marginal arterial perfusion. In venous insufficiency, elevation promotes venous drainage. Applying venous rules to an arterial patient causes harm.

5. Compression is CONTRAINDICATED in PAD. Never apply compression stockings, ACE wraps, or SCDs to a limb with arterial insufficiency. This is the inverse of venous insufficiency treatment. On NCLEX, a question showing compression applied to an ischemic limb is asking you to identify the error.

6. Smoking cessation is the #1 intervention. Regardless of what other management options appear in the question, smoking cessation is the most impactful modifiable risk factor and should always be identified as the priority education point.

7. Claudication relief pattern distinguishes PAD from spinal stenosis. PAD claudication is relieved by stopping to stand still (rest restores perfusion). Neurogenic claudication from spinal stenosis requires sitting or forward bending for relief. Both cause leg pain with walking — the relief mechanism is the differentiator.

8. Ischemic ulcers are painful; neuropathic ulcers are painless. Patients with both PAD and diabetic neuropathy may have painless ischemic ulcers — the neuropathy masks the pain signal. Do not use absence of pain to rule out critical ischemia in diabetics.

9. Supervised exercise therapy is first-line for claudication — before pharmacotherapy and before revascularization in patients with claudication only (not critical limb ischemia). NCLEX may test whether students default to revascularization when exercise therapy is the appropriate first step.

10. The 6 Ps indicate acute arterial occlusion — a surgical emergency. Pallor, Pulselessness, Pain, Paresthesia, Paralysis, Poikilothermia. Contrast with chronic PAD where findings are gradual: diminished (not absent) pulses, atrophic skin, claudication. Sudden onset of the 6 Ps requires immediate vascular surgery notification.

11. Statin therapy in PAD is non-negotiable regardless of LDL. Unlike primary prevention, where statin initiation depends on lipid levels and risk score, any patient with established PAD should be on high-intensity statin therapy for plaque stabilization and cardiovascular event reduction. NCLEX may present a patient with “normal cholesterol” and PAD — the statin is still indicated.

12. Avoid heating pads in PAD. Increased tissue metabolic demand from heat cannot be met by the ischemic arterial supply. In patients with neuropathy, burn injury may go undetected. This is a high-priority patient education teaching point tested on NCLEX.

Related resources

• DVT nursing reference — venous thromboembolism: contrast with arterial disease in mechanism, presentation, and management
• Hypertension nursing reference — HTN management as a primary PAD risk factor
• Diabetes mellitus nursing reference — DM-related vascular complications and foot care
• Heart failure nursing reference — cilostazol contraindication and shared cardiovascular risk
• Wound assessment reference — ischemic wound evaluation and care principles
• Cardiovascular medications nursing reference — antiplatelet agents, statins, and ACE inhibitors in depth
• Aortic dissection nursing reference — acute arterial emergency; contrast with acute limb ischemia
• Sepsis nursing reference — recognition and management of infection complicating critical limb ischemia

Sources: Gerhard-Herman MD, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. J Am Coll Cardiol. 2017;69(11):e71–e126. Aboyans V, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases. Eur Heart J. 2018;39(9):763–816. Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality. JAMA. 2008;300(2):197–208. McDermott MM, et al. The ankle brachial index as a predictor of cardiac risk and peripheral arterial disease. JAMA Intern Med. 2013. Norgren L, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(1 Suppl):S5–67. StatPearls: Peripheral Arterial Disease. National Center for Biotechnology Information (NCBI). Updated 2024.